Biopharmaceutical stock AstraZeneca PLC (NASDAQ:AZN) is 1.3% lower before the open, after a bear note from Deutsche Bank. The analyst downgraded AZN to "sell" from "hold" and lowered its price target, pointing to the company's results from a lung cancer trial that showed its experimental precision drug did not improve overall survival.Coming into today, most analysts were bullish on AstraZeneca stock. Of the 14 in coverage, 11 rated it a "buy" or better, and the 12-month average target price of $90.89 is a ...

thelinke/E+ via Getty Images Shares of AstraZeneca (NASDAQ:AZN) declined earlier this week after the company and its partner Daiichi Sankyo (OTCPK:DSNKY) presented disappointing overall survival data from the phase 3 trial of the antibody-drug conjugate (‘ADC’) candidate datopotamab deruxtecan, or Dato-DXd, in patients with advanced non-squamous non-small cell lung cancer. Dato-DXd is part of AstraZeneca’s expanding ADC pipeline, and part of a greater effort to offer better treatment options for lung ca ...

KEY TAKEAWAYSA Phase 3 trial found AstraZeneca's experimental lung cancer drug datopotamab deruxtecan did not significantly improve patients' overall survival rates.The results from the trial showed that the overall survival rate "did not reach statistical significance," the company said.AstraZeneca shares fell in early trading Tuesday following the news, before recovering later in the session. A Phase 3 trial found AstraZeneca's (AZN) experimental lung cancer drug datopotamab deruxtecan (Dato-DXd) did not ...

The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 monthsBOSTON and ROLLE, Switzerland, Sept. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™, first announced in October 2023. Under a definitive partnership agreement with AstraZenec ...

An illustrative image of a person holding a medical syringe and a Covid-19 vaccine vial in front of the the AstraZeneca logo displayed on a screen. On Wednesday, January 12, 2021, in Edmonton, Alberta, Canada. (Photo by Artur Widak/NurPhoto via Getty Images)AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.The Covid-19 vaccine maker was trading at the bottom of the FTSE ...

These stocks are all up more than 20% this year.You don't have to look at top tech stocks to find good investments to buy and hold. There are many good stocks you can buy for less than $100 that are beating the market today and can continue to do so for years to come. The businesses listed below have strong fundamentals, and with some promising growth opportunities, it may still not be too late to invest in them.AstraZeneca (AZN -3.21%), Chewy (CHWY -3.65%), and Chipotle Mexican Grill (CMG -0.58%) are all d ...

Key TakeawaysFive current and former AstraZeneca employees have reportedly been detained in China in connection with a pair of investigations.The investigations concern the importation of an unapproved liver cancer drug and alleged violations of data privacy laws.A Bloomberg report said the employees who worked in AstraZeneca's oncology department are Chinese citizens. Five current and former AstraZeneca (AZN) employees have been detained by police in China in connection with alleged violations of data priv ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

The office building of biopharmaceutical company AstraZeneca is being seen in Shanghai, China, on May 23, 2024.Some employees of British pharmaceutical giant AstraZeneca have been detained by police in China as part of an investigation, the company confirmed Thursday."We are aware a small number of our employees in China are under investigation and we have no further information to share at this point," an AstraZeneca spokesperson told CNBC by email, without disclosing details on what the investigation conc ...

QIAGEN N.V. (QGEN) has expanded its Master Collaboration Agreement with AstraZeneca (AZN) to develop and commercialize companion diagnostics (CDx) for AstraZeneca’s future therapies targeting chronic diseases. The collaboration will see QIAGEN developing and validating a genotyping assay using its QIAstat-Dx syndromic testing platform.The recent development is poised to enhance the company’s Molecular Diagnostics business.Significance of QIAGEN’s Expanded PartnershipThe new QIAstat-Dx genotyping assay, bein ...